62 chronic hepatitis B patients (having liver enzym level 2 times higher than normal level) were treated orally by 100mg lamivudine a day. After 1 year treatment, in 24/62 cases (38%), HBeAg(+) serum sustainable HBeAg seroconversion was 53% in 6 months follow up after lamivudin discontinouation. Liver enzymes level become normal and no serious adverse reaction was notified.
Hepatitis B, Chronic ; Lamivudine ; Patients ; Therapeutics